Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

• Glavni autori: Gui-Ling Chen (Autor), Yuan-Zheng Qiu (Autor), Kai-Qi Wu (Autor), Ying Wu (Autor), Yuan-Hui Wang (Autor), Yu-Ying Zou (Autor), Cong-Gao Peng (Autor), Jie Zhao (Autor), Chang Su (Autor), Jun-Heng Ma (Autor), Shao-Nan Ni (Autor), Xing Wang (Autor), Ting-Han Jin (Autor), Qi Jiang (Autor), Tong Guo (Autor), Yan Xu (Autor), Chao-Chao Huang (Autor), Qing Zhang (Autor), Kai-Li Liu (Autor), Li Ji (Autor), Han-Yu Yang (Autor), Chun-Lei Li (Autor), Yu-Wen Su (Autor), Xiang Lu (Autor), Lan-Juan Li (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

ABSTRACTVaccination plays a key role in preventing morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the safety and immunogenicity of a SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine SYS6006. In the two randomized, observer...